Tags

Type your tag names separated by a space and hit enter

Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis.
Ann Pharmacother. 2008 Jan; 42(1):32-8.AP

Abstract

BACKGROUND

The behavioral and psychological symptoms related to dementia (BPSD) are difficult to manage and are associated with adverse patient outcomes.

OBJECTIVE

To systematically analyze the data on memantine in the treatment of BPSD.

METHODS

We searched MEDLINE, EMBASE, Pharm-line, the Cochrane Centre Collaboration, www.clinicaltrials.gov, www.controlled-trials.com, and PsycINFO (1966-July 2007). We contacted manufacturers and scrutinized the reference sections of articles identified in our search for further references, including conference proceedings. Two researchers (IM and CF) independently reviewed all studies identified by the search strategy. We included 6 randomized, parallel-group, double-blind studies that rated BPSD with the Neuropsychiatric Inventory (NPI) in our meta-analysis. Patients had probable Alzheimer's disease and received treatment with memantine for at least one month. Overall efficacy of memantine on the NPI was established with a t-test for the average difference between means across studies, using a random effects model.

RESULTS

Five of the 6 studies identified had NPI outcome data. In these 5 studies, 868 patients were treated with memantine and 882 patients were treated with placebo. Patients on memantine improved by 1.99 on the NPI scale (95% Cl -0.08 to -3.91; p = 0.041) compared with the placebo group.

CONCLUSIONS

Initial data appear to indicate that memantine decreases NPI scores and may have a role in managing BPSD. However, there are a number of limitations with the current data; the effect size was relatively small, and whether memantine produces significant clinical benefit is not clear.

Authors+Show Affiliations

Maidment ID
Kent & Medway NHS and Social Care Partnership Trust, Kent Institute of Medicine and Health Studies, University of Kent, Kent, England. ian.maidment@nhs.net
Fox CG
No affiliation info available
Boustani M
No affiliation info available
Rodriguez J
No affiliation info available
Brown RC
No affiliation info available
Katona CL
No affiliation info available

MeSH

AgedAlzheimer DiseaseBehavioral SymptomsDementiaExcitatory Amino Acid AntagonistsFemaleHumansMaleMemantineModels, StatisticalPsychiatric Status Rating ScalesRandomized Controlled Trials as Topic

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

18056833

Citation

Maidment, Ian D., et al. "Efficacy of Memantine On Behavioral and Psychological Symptoms Related to Dementia: a Systematic Meta-analysis." The Annals of Pharmacotherapy, vol. 42, no. 1, 2008, pp. 32-8.
Maidment ID, Fox CG, Boustani M, et al. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008;42(1):32-8.
Maidment, I. D., Fox, C. G., Boustani, M., Rodriguez, J., Brown, R. C., & Katona, C. L. (2008). Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. The Annals of Pharmacotherapy, 42(1), 32-8.
Maidment ID, et al. Efficacy of Memantine On Behavioral and Psychological Symptoms Related to Dementia: a Systematic Meta-analysis. Ann Pharmacother. 2008;42(1):32-8. PubMed PMID: 18056833.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. AU - Maidment,Ian D, AU - Fox,Chris G, AU - Boustani,Malaz, AU - Rodriguez,Jorge, AU - Brown,Ruth C, AU - Katona,Cornelius L, Y1 - 2007/12/04/ PY - 2007/12/7/pubmed PY - 2008/1/26/medline PY - 2007/12/7/entrez SP - 32 EP - 8 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 42 IS - 1 N2 - BACKGROUND: The behavioral and psychological symptoms related to dementia (BPSD) are difficult to manage and are associated with adverse patient outcomes. OBJECTIVE: To systematically analyze the data on memantine in the treatment of BPSD. METHODS: We searched MEDLINE, EMBASE, Pharm-line, the Cochrane Centre Collaboration, www.clinicaltrials.gov, www.controlled-trials.com, and PsycINFO (1966-July 2007). We contacted manufacturers and scrutinized the reference sections of articles identified in our search for further references, including conference proceedings. Two researchers (IM and CF) independently reviewed all studies identified by the search strategy. We included 6 randomized, parallel-group, double-blind studies that rated BPSD with the Neuropsychiatric Inventory (NPI) in our meta-analysis. Patients had probable Alzheimer's disease and received treatment with memantine for at least one month. Overall efficacy of memantine on the NPI was established with a t-test for the average difference between means across studies, using a random effects model. RESULTS: Five of the 6 studies identified had NPI outcome data. In these 5 studies, 868 patients were treated with memantine and 882 patients were treated with placebo. Patients on memantine improved by 1.99 on the NPI scale (95% Cl -0.08 to -3.91; p = 0.041) compared with the placebo group. CONCLUSIONS: Initial data appear to indicate that memantine decreases NPI scores and may have a role in managing BPSD. However, there are a number of limitations with the current data; the effect size was relatively small, and whether memantine produces significant clinical benefit is not clear. SN - 1542-6270 UR - https://www.unboundmedicine.com/medline/citation/18056833/Efficacy_of_memantine_on_behavioral_and_psychological_symptoms_related_to_dementia:_a_systematic_meta_analysis_ DB - PRIME DP - Unbound Medicine ER -